ProCE Banner Activity

Phase I Studies of Selective EGFR/HER2 Inhibitor DZD9008 in Patients With Advanced NSCLC and EGFR Exon 20 Insertion Mutations

Slideset Download
Conference Coverage
EGFR/HER2 inhibitor DZD9008 was well tolerated with promising antitumor activity in patients with EGFR ex20ins mutation–positive advanced NSCLC with or without brain metastasis.

Released: September 20, 2021

Expiration: September 19, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme